INTRODUCTION
Bone marrow transplantation is being employed with increasing frequency in the management of acute leukemia and aplastic anemia (for review see 1) . Although steady improvement in results has been achieved, a number of problems continue to limit long-term success. Among the most frequent causes of morbidity and mortality in these patients are graft vs. host disease (GVHD)1 (2) and severe infections with a variety of bacterial, viral, fungal, and protozoal organisms (2) (3) (4) .
The factors responsible for the high incidence of infections are poorly understood at present. During the early postgrafting period, granulocytopenia is undoubtedly a major factor, since successful engraftment as defined by an absolute granulocyte count of 500/mm' or greater does not usually occur for 2-4 wk (1) . The use of immunosuppressive drugs (1) may also increase susceptibility to infection. A marked increase in mortality from infection has been noted in marrow transplant patients who develop severe GVHD (2) , suggesting the possibility of compromised host defense mechanisms in this group in particular. Studies of both human and canine marrow graft recipients have demonstrated de-mal granulocyte iodination and nitroblue tetrazolium reduction were reported in canine marrow graft recipients (7) .
In an attempt to determine whether granulocyte dysfunction may contribute to the increased susceptibility to infection in marrow transplant patients, polymorphonuclear leukocyte (PMN) chemotaxis was evaluated after 34 marrow grafts in patients with leukemia or aplastic anemia. A marked decrease in chemotactic responses was observed in a large proportion of these patients. The relationship of this defect to a number of clinical parameters including GVHD and the administration of antithymocyte globulin (ATG) was also examined.
METHODS

Study population. Between November 1973 and August
1975, studies were performed after 34 marrow transplants (see Table I ) in 33 patients, 1 individual receiving a repeat graft after recurrence of leukemia (see Table I , numbers 5 and 29). 12 patients had aplastic anemia, 10 had acute lymphocytic leukemia, 10 Patient management. The technique for performing bone marrow transplantation has been described in detail (1, (9) (10) (11) . Transplants were done between HLA identical siblings whose lymphocytes were nonreactive in mixed leukocyte culture, or in one instance (Table I , number 27) between identical twins. Pregraft preparation in patients with leukemia consisted of cyclophosphamide and total body irradiation (1, 10) . Most patients with aplastic anemia were prepared with cyclophosphamide alone (1, 11), but four (Table I, numbers 1, 2, 3 , and 11) received in addition procarbazine and ATG (12) . After marrow infusion patients were supported with platelet and erythrocyte transfusions, and granulocyte transfusions were given in some instances for treatment of bacterial infection occurring before successful engraftment. All patients except the identical twin received methotrexate 15 mg/M2 on day 1 after transplantation and then 10 mg/M2 on day 3, 6, 11, and weekly until day 100.
Many patients developed some manifestations of GVHD during the post-transplantation course. This was graded in severity from I to IV on the basis of previously defined clinical and histologic criteria (2, 13) . GVHD persisting for more than 3 mo or developing beyond 100 days posttransplantation was termed chronic GVHD (2) . Most patients with Grade II-IV and one patient with Grade I GVHD were treated with ATG raised in rabbits, goats, or horses and given in a dose of 7 mg/kg every other day for six doses as previously described (14) . For purposes of analysis, patients with no evidence of GVHD were grouped together with ,those having minimal disease with skin involvement only (Grade I) and compared to those having more advanced disease (Grade II-IV) as in previous reports (2 (15) . After adjusting for variability in specific activity and granulocyte uptake of "Cr, chemotaxis was expressed as corrected counts per minute in the lower filter (15) .
The chemotactic stimuli employed were (a) partially purified human C5a generated by endotoxin activation of serum, eluted from Sephadex G-75 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) and characterized by heat stability, molecular weight (15,000), and inhibition by goat antihuman C5 (16) and (b) endotoxin (Escherichia coli 0127 :B8 lipopolysaccharide B, Difco Laboratories, Detroit, Mich.) activated whole human serum (17) . Patients' cells and serum were always studied concomitantly with cells and serum from one or more normal individuals. For nine of the patients (Table I, numbers 5, 13, 19, 20, 22, 24, 27, 28, and 29) , the bone marrow graft donor sibling was employed for a normal control, while in the remainder healthy laboratory personnel of both sexes ranging in age from 18 to 48 yr were used. According to the experimental protocol normal and patient PMNs were tested against a buffer negative control (gelatin veronal buffer) (17) , C5a, and endotoxin activated normal and patient serum. Each condition was examined in quadruplicate chemotaxis chambers, and the mean response of patient cells expressed as a percent of the mean response of normal cells. The chemotactic activity of patient serum was compared to normal serum in similar fashion.
The possibility of chemotactic inhibitors in the patient's serum was evaluated by comparing the response of normal PMNs suspended in Gey's medium containing 10% patient serum to the response of the same normal PMNs suspended in Gey's medium containing 10%o normal serum (17) . Serum immunoglobulin E levels were measured by radioimmunoassay in a commercial laboratory (Bio-Science Laboratories, Van Nuys, Calif.). All other hematological, chemical, microbiological, and histological studies were performed by standard techniques in the hospital diagnostic laboratories.
The were observed in approximately three-fourths (24 of 34) of all the bone marrow transplant recipients studied.
As detailed in Table I , 14 patients were studied on more than one occasion. Findings remained relatively constant with the exception of isolated patients whose clinical features changed dramatically between studies. Some of these are discussed in a later section as they relate to GVHD and therapy with ATG. Little change was noted in patients 15, 20, 21, 22, 28, 30 , and 33. Patient 23 was studied on 10 separate occasions, with significantly reduced migration being observed in all but one experiment. In patient 24 the first three studies were performed during a period of 3 mo when he experienced two bouts of bacterial pneumonia (Streptococcus pneumoniae and Hemophilus influenzae) ; all showed decreased chemotactic responses. Subsequently, the chemotaxis values increased to normal levels, and infections ceased to be a problem.
Correlation of chemotaxis with clinical parameters.
A number of important clinical features of the patients were examined to determine which factors might be associated with the depressed PMN chemotactic response. There was a tendency for better PMN chemotactic responses in patients with acute lymphocytic leukemia relative to those with either aplastic anemia (0.05 < P < 0.1) or acute myelocytic leukemia (P < 0.05). Age did not appear to be a determinant of the chemotactic response since no significant differences were noted among 
Serum IgE levels were determined since a number of patients with recurrent infections, defective PMN chemotaxis, and hyperimmunoglobulinemia E have been reported (18) (19) (20) (21) (22) . Normal values (< 300 U/ml) were observed in most patients, but elevated levels were present in nine individuals (six in Group A, two in Group B, and one in Group C). In six of these, values were between 600 and 900 U/ml, but more marked elevations were noted in patients 4, 5, and 15 (1,050, 3,379, and 1,051 U/ml, respectively), all of whom had severely depressed chemotaxis. The hyperimmunoglobulinemia E may be related to GVHD since eight of the nine patients with elevated levels had Grade III-IV GVHD and three of four patients with chronic GVHD had high IgE levels.
The possible contribution of drugs to the chemotaxis results was examined carefully. All patients studied within 100 days of marrow infusion (except for the 1 identical twin, patient 27) were receiving weekly methotrexate; this included 17 of 24 with decreased PMN chemotaxis (Groups A and B) and 8 of 10 with normal chemotaxis (not significant). 24 Group A and B patients (14 episodes in 10 patients) than in the 10 Group C patients (1 episode), this difference did not prove to be significant (P = 0.068, Fisher exact test; 0.05 <P < 0.1, t test). Bacterial pneumonia (10 episodes in six patients) and meningitis (2 episodes) occurred exclusively in patients with depressed chemotactic responses. A total of 20 cases of bilateral interstitial pneumonia (3) were observed, 5 due to cytomegalovirus, 2 due to varicella-zoster, 4 due to Pneumocystis carinii, and 9 of unproven etiology. These 20 infections occurred in 13 Group A and B patients (14 infections) and 5 Group C patients (6 infections), (difference not significant). Of 13 proven viral infections, 10 were seen in 8 different Group A and B patients and 3 in Group C patients (not significant). All four cases of disseminated fungal infection occurred in Group A and B patients, although this was not a statistically significant finding. The differences in infections described could not be attributed to differences in follow-up, since the period of observation was similar in all groups (see Methods). Death due to infection (mostly interstitial pneumonia) occurred in 13 patients with depressed chemotaxis and in 4 patients with normal chemotaxis. Thus, defective chemotaxis in these patients was associated with an increased incidence of serious infections caused predominantly by bacterial pathogens. Fungi may possibly be implicated as well, but the incidence of viral predominantly in patients with Grade II-IV GVHD or recent ATG therapy or both. In fact, all but one patient (number 6) in Group A had one or both of these risk factors present, while 8 of the 10 patients with normal chemotaxis (Group C) had neither of these factors * present. Since GVHD and ATG were generally associated, attempts were made to examine them separately. Fig. 1 illustrates the chemotactic responses as a function of GVHD and ATG administration. Some patients appear more than once in Fig. 1 rho changed from one cate-(P < 0.01) in eight subjects. The effect of ATG in the hemotaxis studies, the aver-absence of Grade II-IV GVHD was examined in a small category is depicted. Hori-group of three patients, two of whom (numbers 2 and r each category. All values 11) received ATG as part of their pregraft preparation, ficantly reduced from nor-and one (number 16) who was treated for early Grade I GVHD. The mean response in these three patients was 17 .0±7.8 (P < 0.02).9 umonia did not correlate Serial chemotaxis studies in some patients were of interest in assessing the role of GVHD and ATG. Pashowed striking correla-tient 10 with Grade IV GVHD had responses before nt administration of ATG. and 18 days after treatment with ATG of 31 and 5%, sent at the time of study respectively. Patient 13 had a response of 22% in the 3 of 6 Group B patients, presence of GVHD; this decreased to 7% one day after P < 0.01, 3 X 2 chi-square ATG, although subsequent values 30 and 116 days after *d ATG within 100 days ATG were 33 and 28%, respectively. On the other hand, 22±6 days) were concen-patient 17 with GVHD had nearly identical chemotaxis 22* ects) ncra none values of 30 and 31% before and 3 days after ATG. ubjects). In contrast, nonev in Group C had been so In patient 19 (who received no ATG), values of 37 and luare test); the remaining 2One identical twin (patient 27) received a syngeneic iATG or in two instances graft and was thus not at risk for GVHD; this patient had rval before study (> 200 normal chemotaxis. Since initial submission of the manudays in patient 29). Se-script, three additional twins with syngeneic grafts have -been evaluated and found to have normal PMN chemotaxis ;ponses therefore occurred (95.1, 78.4, and 71.5%o).
42% were seen before GVHD, and 39% after developing chronic GVHD. Interestingly, patient 29 was doing well 1j yr after transplantation and had normal chemotaxis (102%), but after leukemic relapse and a repeat transplant (new patient number 5), developed GVHD, was given ATG, and on two occasions had severely reduced PMN chemotaxis (4 and 8%).
In vitro effect of ATG. Further evidence for a suppressive effect of ATG on chemotaxis was obtained by treating normal PMNs with ATG in vitro. A potent inhibitory effect was observed (see Fig. 2 ). The highest dilutions showing significant inhibition were 1: 4,000, 1: 1,000 and 1: 100 for the rabbit, horse, and goat preparations, respectively. Normal rabbit serum at dilutions of 1: 100 or 1: 1,000 had no inhibitory effect. This inhibition by ATG was not attributable to reversal of the chemotactic gradient or to chemotactic deactivation, since ATG was also inhibitory when mixed with the chemotactic factor, and when ATG alone was placed in the lower compartment no chemotactic activity was detected. Using a 1: 100 dilution of rabbit ATG the chemotactic inhibitory effect was not reversible by washing and resuspending the PMNs in fresh medium (mean inhibitory activity with and without washing 94.5 and 95.9%, respectively). Thus, the inhibition appeared to be due to a direct effect of ATG on the PMNs rather than an inactivation of the chemotactic attractant. Absorption of rabbit ATG with three serial changes of normal human PMNs resulted in a final supernate which caused 64.0% inhibi- tion of chemotaxis compared to 96.5% inhibition by control ATG carried through identical processing except for omission of the PMNs (P < 0.02). This partial absorption of inhibitory activity by neutrophils is compatible with the presence of antineutrophil antibody in the ATG. The chemotactic inhibitory activity did not appear to result from a cytotoxic effect of ATG on the neutrophils; using the same conditions as those employed in the chemotaxis assay (see Methods), neither rabbit, horse, nor goat ATG in dilutions of 1: 100 or 1: 1,000 caused any release of 'Cr above negative control values.
Serum chemotactic activity and inhibitors. The PMN chemotactic activity generated by activation of patients' serum with endotoxin was not significantly reduced from normal in all but five subjects (numbers 1, 8, 20, 25, and 30) . Activity in these five sera ranged from 13 to 55% of normal. Serum chemotactic activity did not show significant correlation with PMN chemotactic responses or with the clinical parameters examined, although four of the five patients had GVHD and three had received ATG.
Chemotactic Because of the high incidence of fatal GVHD in marrow graft recipients the use of ATG has recently been advocated for the treatment of established GVHD (14) . Although this has favorably modified the graft vs. host reaction, many treated patients develop fatal infections, particularly viral interstitial pneumonitis (14) . Administration of ATG to renal transplant patients has been associated with an increased incidence of infections due primarily to bacterial pathogens (23) . Lymphocytes from ATG treated patients do not react to allogeneic cells in mixed leukocyte cultures due in part to a plasma inhibitor which may persist for weeks after discontinuing ATG (14) . One of the toxic effects observed with ATG was the development of m-yelosuppression with granulocytopenia in a small proportion of patients (14) . A slight decrease in neutrophil bactericidal capacity has been reported in ATG treated kidney allograft recipients (24) . The current study raises the possibility that ATG treatment may have deleterious effects on neutrophil chemotaxis.
The mechanism of interference with PMN chemotaxis by ATG has not been determined. However, the in vitro demonstration of a direct suppressive effect of ATG on chemotaxis of normal PMNs suggests that this material could have a similar effect in vivo. Interestingly, ATG employed under conditions which markedly suppressed PMN chemotaxis had no detectable cytotoxic effect on PMNs as judged by a rnCr-release assay. ATG is a globulin fraction from the serum of animals immunized with human thymus (14) and may contain antibodies with specificity or cross-reacting activity against cells other than thymocytes or lymphocytes, e.g. neutrophils. If this were the case, the potential for PMN dysfunction might be abrogated by absorption with neutrophils. Indeed, significant reduction in chemotactic inhibitory activity was achieved by absorbing ATG with normal PMNs; however, the partial nature of this reduction under the conditions employed suggests the presence of both absorbable and nonabsorbable inhibitors. Absorption with erythrocytes has been proposed to avoid the hemolytic anemia seen in some ATG treated patients (14) . Unfortunately, absorption might also reduce the immunosuppressive properties of ATG.
Factors in addition to GVHD and ATG administration could well be involved in the diminished chemotactic response. Although no other specific factors were identified, the finding of depressed chemotaxis in a limited number of patients without GVHD or ATG administration supports such a possibility. Furthermore, the presence of both GVHD and ATG treatment was not invariably associated with defective chemotaxis since 2 of 15 such patients had normal migration.
In most patients a cellular abnormality was implicated as the basis for defective PMN chemotaxis. In some subjects the neutrophils may have been damaged in situ by a humoral agent such as an antineutrophil component of ATG. However, serum inhibitors of chemotaxis were detected in only 6 of 24 patients with diminished PMN migration and in 1 with a normal response. Hyperimmunoglobulinemia E was noted primarily in patients with GVHD. The role of this abnormality in the chemotactic defect remains unknown, although the levels observed were not as markedly elevated as in most of the patients described with high IgE and depressed PMN chemotaxis (18) (19) (20) (21) (22) . Serum chemotactic activity was decreased in 5 of 34 patients. A similar serum defect has been described in a single marrow transplant patient (8) ; the decreased serum opsonic activity also observed in this patient appeared to be related to a serum inhibitor of opsonization.
Numerous examples of an increased incidence of infections in patients with chemotactic abnormalities have been described (for reviews see [25] [26] [27] . The patients in the current series with decreased PMN chemotaxis had a marked and statistically significant increase in incidence of infections relative to those with normal PMN responses. Bacterial infections including septicemia, meningitis, cellulitis, abscesses, pneumonitis, and other sinopulmonary infections were primarily responsible.
In contrast, viral infections and interstitial pneumonia occurred with equal frequency in patients with decreased or normal chemotaxis. The data suggest that neutrophil dysfunction may be at least partially responsible for the high incidence of bacterial and possibly fungal infections in bone marrow transplant patients, particularly those with GVHD. It has been shown that infection itself may in some instances depress the PMN chemotactic response (28) (29) (30) (31) . This effect may be of particular significance in severely ill patients with toxic neutrophils (28), a finding not encountered at the time of study in our patients. Several other reports have noted a consistent enhancement of PMN chemotaxis in most patients with acute pyogenic infections (32) (33) (34) . The latter studies dealt primarily with children and young adults, an age range similar to that of the marrow transplant patients evaluated in the current report.
The findings reported here may have implications for the management of bone marrow transplant patients. Even after engraftment with the appearance of normal numbers of blood granulocytes, serious and recurrent infections remain a major risk. Suspected infection must be treated vigorously, especially in patients who have manifestations of GVHD or who have been treated with ATG. Although the use of ATG has proven to be valuable in suppressing the graft vs. host response (14) , the high incidence of infections in ATG-treated patients (14, 23) , together with the current results demonstrating suppression of PMN chemotaxis, suggest the need for continued evaluation of improved means for preparing and administering this agent. Finally, the use of granulocyte transfusions in the treatment of infections should be considered not only in granulocytopenic patients, but also in those who may have neutrophil dysfunction.
